Eden Lake’s scientific contributions

... This figure significantly drops in man and woman that are non-hispanic white with a 0.09% death rate (1 in 11 for woman and 1 in 7 for man). Dawes Sm et al. in a 2016 study claims "a serious disparity exists in melanoma diagnosis and outcome for white patients compared with minorities" [35]. The high death disparity in black melanoma patients compared to their white counterparts is not rooted in biological differences, but socioeconomic factors. ...

Reference:

AI Skin Condition Diagnostic with a Precision Higher than Physicians: A Deep Learning Approach

... As a result, unnecessary blood draws and health costs may be avoided. 56,57 Comments and conclusions Guideline recommendations aim to improve patient care based on the existing scientific evidence of best available quality at the time of their writing, regarding effectiveness and safety of treatments. However, there are limitations in the existing evidence and guidelines. ...

Reference:

Comparison of guidelines and consensus articles on the management of patients with acne with oral isotretinoin

... This disfiguring disorder remains a big challenge to dermatologists, as the current treatment options may improve the appearance temporarily but cannot achieve a complete remission or prevent recurrence [3]. Oral tranexamic acid (TA), a procoagulant agent reported previously, has now been proved to be promising in the field of melasma treatment with convincing efficacy and safety, particularly for the refractory and recurrent patients [4]. ...

Reference:

Tranexamic acid inhibits melanogenesis partially via stimulation of TGF‐β1 expression in human epidermal keratinocytes

... [63] Dupilumab Dupilumab is a fully human monoclonal antibody directed against the IL-4a receptor a-subunit, which blocks the signaling of both IL-4 and IL-13, the two key drivers of type 2 immune response. [64] In 2017, dupilumab was approved by the US Food and Drug Administration (FDA) for treatment of moderate to severe AD in patients 18 years of age and older. A systematic review and meta-analysis of efficacy and safety of dupilumab treatment in moderate to severe AD provided evidence that dupilumab had an acceptable safety profile and resulted in clinically relevant improvements in signs and symptoms of AD. [65] Omalizumab Limited data exist to determine the efficacy of omalizumab in the treatment of AD. ...

Reference:

Guidelines on Management of Atopic Dermatitis in India- An Evidence-Based Review and an Expert Consensus